Hakam Safadi, MD
Pulmonary Disease · Merrillville, INNPI 1851394134
Payments from drug & device makers
What this record shows
This record is dominated by other: $17,208 of the $24,267 with a category attached, or 70.9%. Philips North America LLC accounts for 71.1% of it on its own, with 39 other manufacturers making up the rest. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 394 payments — averaging $61.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$17K
- Mallinckrodt Hospital Products Inc.$1K
- AstraZeneca$1K
- GSK$1K
- Boehringer Ingelheim$540
- Actelion Pharmaceuticals US, Inc.$451
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,57827%
- Education$4812%
- Other$17,20871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 11 | $17,261 |
| Mallinckrodt Hospital Products Inc. | 36 | $1,137 |
| AstraZeneca | 59 | $1,079 |
| GSK | 111 | $1,067 |
| Boehringer Ingelheim | 24 | $540 |
| Actelion Pharmaceuticals US, Inc. | 15 | $451 |
| Sunovion Pharmaceuticals Inc. | 33 | $414 |
| Intuitive Surgical | 3 | $170 |
| Insmed, Inc. | 9 | $162 |
| Galvanize Therapeutics, Inc | 2 | $160 |
| Inari Medical, Inc. | 1 | $157 |
| ANI Pharmaceuticals, Inc. | 6 | $146 |
| Mylan Specialty L.p. | 9 | $143 |
| Sanofi | 7 | $139 |
| Electromed, Inc. | 9 | $122 |
| Merck | 7 | $101 |
| Jazz Pharmaceuticals Inc. | 4 | $94 |
| Regeneron Healthcare Solutions, Inc. | 4 | $88 |
| Advanced Respiratory, Inc | 3 | $86 |
| United Therapeutics Corporation | 5 | $81 |
| Pfizer | 5 | $81 |
| Amgen | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $73 |
| Harmony Biosciences LLC | 2 | $57 |
| AbbVie(2 entities) | 2 | $53 |
| Covis Pharma GmbH | 2 | $34 |
| Novartis | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $29 |
| Lilly USA, LLC | 1 | $25 |
| Genentech USA, Inc. | 2 | $24 |
| Baxter Healthcare | 1 | $20 |
| Verona Pharma, Inc. | 1 | $19 |
| Inogen, Inc. | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| ZOLL Medical Corporation | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| Veran Medical Technologies, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,267 in reported general payments places this provider in the 90th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 51 | $611,804 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 324 | $278,688 |
| AdempasRiociguat | 12 | $168,927 |
| Breo ElliptaFluticasone/Vilanterol | 108 | $64,153 |
| Pirfenidone | 21 | $59,297 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $43,557 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $32,942 |
| Spiriva RespimatTiotropium Bromide | 38 | $24,525 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 75 | $7,803 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $6,939 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,730 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 279 | $6,439 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $5,677 |
| Theophylline ErTheophylline Anhydrous | 13 | $4,848 |
| Fluticasone Propionate HfaFluticasone Propionate | 12 | $4,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $540 | $643,059103 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,067 | $382,723504 claims |
| BayerAdempas | $13 | $168,92712 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,079 | $49,23478 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $32 | $2,35214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Merrillville
- Bilal SafadiMerrillville$13K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.